Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Herpes Zoster Clinical Trial

Official title:

Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02058589
• Other study ID #: 116886
• Secondary ID: 2012-005059-18
• Status: Completed
• Phase: Phase 3
• Start date: March 20, 2014
• Est. completion date: April 13, 2017

Study information

• Verified date: June 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 265
• Est. completion date: April 13, 2017
• Est. primary completion date: May 11, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.

• A male or female, aged 18 years or older and having reached the age of legal consent, on the date the informed consent is signed.

• Written informed consent obtained from the subject.

• Subject who has received an ABO compatible allogeneic renal transplant.

• Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to the first vaccination.

• Subject without an episode of allograft rejection over the previous three months (90 days) prior to the first vaccination.

• Subject with stable renal function, stability defined as:

• less than 20% variability between last two creatinine measurements or calculated GFR

• or in the opinion of the investigator after investigator review of more than the last two creatinine measurements or calculated GFRs.

• Subject not less than 4 months (120 days) and not more than 18 months (547 days) after allograft transplantation at the time of the first vaccination.

• Subjects with multiple dialysis options (peritoneal and/or more than one anatomical access site for haemodialysis) in the event acute or chronic dialysis is needed.

• Female subjects of non-childbearing potential may be enrolled in the study.

• Female subjects of childbearing potential may be enrolled in the study, if the subject:

• has practiced adequate contraception for 30 days prior to vaccination, and

• has a negative pregnancy test on the day of the first vaccination, and

• has agreed to continue adequate contraception during the primary treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

• Any primary kidney disease with a high incidence of recurrent primary kidney disease.

• Evidence of recurrent primary kidney disease within the current allograft.

• Previous allograft loss secondary to recurrent primary kidney disease.

• Multiple kidney transplants are allowed if the reason for a previous allograft's loss is not recurrent primary kidney disease.

• More than one organ transplanted (i.e. kidney-liver, double kidney or kidney-other organ(s) transplanted).

• History of events that, in the opinion of the investigator, may put subject at increased risk for chronic allograft dysfunction (e.g. delayed graft function, peri-operative complications).

• Histologic reports of chronic allograft injury (e.g. transplant glomerulopathy, arteriopathy, C4d deposition).

• Evidence of significant proteinuria in the opinion of the investigator.

• Panel reactive antibody score (PRA or cPRA) that is unknown at the time of transplant.

• Any autoimmune or potential immune-mediated disease including primary kidney disease.

• Use of anti-CD20 or other B-cell monoclonal antibody agents (e.g., rituximab) as induction, maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months (274 days) of first dose of study vaccine/placebo.

• Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.

• Concurrent or planned participation in another clinical study, at any time during the study period, which has exposed or will expose the subject to an investigational or a non-registered product

• Administration or planned administration of a live vaccine within 30 days prior to the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.

• Planned administration during the study of a varicella or HZ vaccine other than the study vaccine.

• Previous vaccination against HZ or varicella within the 12 months preceding the first dose of study vaccine/placebo.

• Occurrence of varicella or HZ per clinical history, within the 12 months preceding the first dose of study vaccine/placebo.

• Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit.

• Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of induction and/or maintenance immunosuppressive therapies.

• Any confirmed or suspected HIV, primary immunodeficiency disease, disseminated or untreated malignancy, or systemic infection.

• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or study material and equipment.

• Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.

• Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.

• Acute disease and/or fever at the time of vaccination.

• Fever is defined as temperature = 37.5°C /99.5°F by oral route. The preferred route for recording temperature in this study will be oral.

• Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 3.

Related Conditions & MeSH terms

• Herpes Zoster

Intervention

Biological:
• Herpes Zoster vaccine GSK1437173A
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Drug:
• Placebo
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Brussels
Belgium	GSK Investigational Site	Bruxelles
Belgium	GSK Investigational Site	Gent
Belgium	GSK Investigational Site	Leuven
Canada	GSK Investigational Site	Edmonton	Alberta
Canada	GSK Investigational Site	Halifax	Nova Scotia
Canada	GSK Investigational Site	Toronto	Ontario
Canada	GSK Investigational Site	Toronto	Ontario
Czechia	GSK Investigational Site	Hradec Kralove
Finland	GSK Investigational Site	Helsinki
Italy	GSK Investigational Site	Genova	Liguria
Italy	GSK Investigational Site	Milano	Lombardia
Italy	GSK Investigational Site	Parma	Emilia-Romagna
Italy	GSK Investigational Site	Siena	Toscana
Italy	GSK Investigational Site	Treviso	Veneto
Korea, Republic of	GSK Investigational Site	Seoul
Korea, Republic of	GSK Investigational Site	Seoul
Panama	GSK Investigational Site	Panama
Spain	GSK Investigational Site	Barakaldo (Vizcaya)
Spain	GSK Investigational Site	Barcelona
Spain	GSK Investigational Site	Barcelona
Spain	GSK Investigational Site	Cordoba
Spain	GSK Investigational Site	Hospitalet de Llobregat
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Santander
Spain	GSK Investigational Site	Sevilla
Taiwan	GSK Investigational Site	Kaohsiung
Taiwan	GSK Investigational Site	Keelung
Taiwan	GSK Investigational Site	Taichung
Taiwan	GSK Investigational Site	Taipei
Taiwan	GSK Investigational Site	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Belgium,  Canada,  Czechia,  Finland,  Italy,  Korea, Republic of,  Panama,  Spain,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With a Vaccine Response for Anti-glycoprotein E (gE) Humoral Immunogenicity	Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (=) 4 fold the cut-off for Anti-gE (4x97 milli-international units per milliliter [mIU/ml]); For initially seropositive subjects, antibody concentration at post-vaccination = 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by Enzyme-Linked ImmunoSorbent Assay (ELISA).	At Month 2.
Primary	Number of Subjects With Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Pain when limb was moved, which prevented everyday activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.	Within 7 days (Days 0-6) after each dose and across doses.
Primary	Days With Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling.	Within 7 days (Days 0-6) after each dose and overall/dose
Primary	Number of Subjects With Solicited General Symptoms	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)] . Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. Gastrointestinal symptoms (Gastro. sympt.) included nausea, vomiting, diarrhoea and/or abdominal pain.	Within 7 days (Days 0-6) after each dose and across doses
Primary	Days With Solicited General Symptoms	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)].	Within 7 days (Days 0-6) after each dose and overall/dose
Primary	Number of Subjects With Unsolicited Symptoms (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.	During the 30-day (Days 0-29) post-vaccination period
Primary	Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)	pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology	From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Primary	Number of Subjects With Any and Related Serious Adverse Events (SAEs)	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongatoion of hospitalization, or result in disability /incapacity. Related = SAE assessed by the investigator as related to the vaccination.	From first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Primary	Number of Subjects With Renal Allograft Rejection	Renal allograft rejection was confirmed through biopsy.	From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Primary	Number of Subjects With Changes in Allograft Function	Allograft function was indicated by the increase in levels of serum creatinine (= 1.20, = 1.50, = 1.75 or = 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (up to 30 days post-last vaccination) compared to pre-vaccination were presented.	From the first vaccination (Month 0) up to 1 month post last vaccination (Month 2).
Secondary	Anti-gE Antibody Concentrations	Varicella Zoster Virus (VZV) gE antibody Immunoglobulin G concentrations were determined by ELISA assay, presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off value was = 97 mIU/mL.	At Months 0, 1, 2, 7 and 13
Secondary	Number of Subjects With a Vaccine Response for Anti-gE Humoral Immunogenicity	Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination greater than or equal to (=) 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination = 4 fold the pre-vaccination antibody concentration. Vaccine response was determined by ELISA.	At Months 1, 7 and 13
Secondary	Frequencies of gE-specific Cluster of Differentiation 4 (CD4+) T-cells	Descriptive statistics of gE-specific CD4+ T-cells, expressing at least two activation markers (from among interferon gamma [IFN-?], interleukin-2 [IL-2], tumour necrosis factor alpha [TNF-a] and cluster of differentiation 40-ligand [CD40L]) were tabulated, as determined by in vitro Intracellular Cytokine Staining (ICS).	At Months 0, 2 and 13
Secondary	Number of Subjects With a Vaccine Response for gE-specific CD4+ T-cells	Vaccine response for gE-specific CD4+ T-cells expressing at least two activation markers (from among IFN-?, IL-2, TNF-a and CD40L), was determined by in vitro ICS. Vaccine response was defined as: For initially subjects with pre-vaccination T-cell frequencies below the threshold, at least a 2-fold increase as compared to the threshold (2x<320> Events/10 million CD4+ T-cells); For initially subjects with pre-vaccination T-cell frequencies above the threshold, at least a 2-fold increase as compared to pre-vaccination T-cell frequencies.	At Months 2 and 13
Secondary	Number of Subjects With Any and Related SAEs	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related = SAE assessed by the investigator as related to the vaccination.	From 1 month post last vaccination (Month 2) until study end (Month 13).
Secondary	Number of Subjects With Any pIMDs	pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	From 1 month post last vaccination (Month 2) until study end (Month 13).
Secondary	Number of Subjects With Renal Allograft Rejection	Renal allograft rejection was confirmed through biopsy.	From 1 month post last vaccination (Month 2) until study end (Month 13).
Secondary	Number of Subjects With Changes in Allograft Function	Allograft function was indicated by the increase in levels of serum creatinine (= 1.20, = 1.50, = 1.75 or = 2 fold increase). The number of subjects with declining allograft function, as determined by serum creatinine measurements post-vaccination (from 30 days post-last vaccination up to study end) compared to pre-vaccination were presented.	From 1 month post last vaccination (Month 2) until study end (Month 13)